{"id":11243,"date":"2026-01-20T07:37:41","date_gmt":"2026-01-20T12:37:41","guid":{"rendered":"https:\/\/www.packagingindustrynews.com\/?p=11243"},"modified":"2026-01-20T07:37:41","modified_gmt":"2026-01-20T12:37:41","slug":"sharp-to-invest-in-european-injectable-packaging-expansion","status":"publish","type":"post","link":"https:\/\/www.packagingindustrynews.com\/?p=11243","title":{"rendered":"Sharp to invest in European injectable packaging expansion"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \n <\/picture>
The funds will be used to upgrade various injectable types such as autoinjectors, pre-filled syringes, pen devices, and vials. Credit: Rawpixel.com \/ Shutterstock.com. <\/figcaption><\/figure>\n<\/p><\/div>\n

Pharmaceutical packaging company Sharp has committed more than \u20ac20m ($23.4m) to expand its European facilities amid demand for injectable products.<\/p>\n

The funds will be used to upgrade sites in Hamont-Achel, Belgium, and Heerenveen, the Netherlands.<\/p>\n

\n
\n
\"\"\/<\/figure>\n

Discover B2B Marketing That Performs <\/h4>\n

\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n


\n\t\t\t\t\t\t\tFind out more <\/svg><\/span><\/a><\/p>\n<\/section>\n<\/div>\n

The focus will be on enhancing capabilities for assembling, labelling, packaging, and cold storage of various injectable types such as autoinjectors, pre-filled syringes, pen devices, and vials.<\/p>\n

At its Belgian facility, Sharp will increase cold-chain warehouse space fourfold and double ambient storage capacity.<\/p>\n

The site is also set to receive a new suite for syringe assembly and blister packaging.<\/p>\n

Plans are in place to further boost device assembly and packaging operations.<\/p>\n

To support efficiency on adjacent packaging lines for pre-filled syringes and autoinjectors, the company has introduced collaborative robot technology.<\/p>\n

A new solar-powered carport has also been installed at the Hamont-Achel site to provide renewable energy.<\/p>\n

Once fully commissioned by mid-2026, this system is expected to supply 50% of the facility\u2019s electricity needs from renewable sources.<\/p>\n

The Heerenveen site in the Netherlands will see an expansion of GMP production capabilities through the addition of two Grade D packaging suites.<\/p>\n

These improvements aim to support upcoming syringe assembly and packaging projects, as well as increased vial packaging capacity planned for 2026.<\/p>\n

Sharp Clinical & Sharp Europe managing director Robert O\u2019Beirn said: \u201cOur European facilities have a long-established reputation for successfully delivering the complex packaging services required for injectable drug formats. <\/p>\n

\u201cThis investment represents a significant increase in our capacity to support our pharma clients, as sustainably as possible, with their injectable drug launches in the EU market.\u201d<\/p>\n

This European expansion forms part of a broader $100m investment programme announced by Sharp in November 2025.<\/p>\n

In May 2024, the company expanded its Macungie facility<\/a> in Pennsylvania, US, to address greater demand for secondary packaging of sterile injectables.<\/p>\n

<\/p>\n

<\/p>\n

\n